Stocklytics Platform
Asset logo for symbol ITCI
Intra-Cellular Therapies
ITCI67
$77.63arrow_drop_up0.85%$0.66
Asset logo for symbol ITCI
ITCI67

$77.63

arrow_drop_up0.85%

Performance History

Chart placeholder
Key Stats
Open$77.00
Prev. Close$76.97
EPS-0.86
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range76.80
78.15
52 Week Range45.50
84.89
Ratios
EPS-0.86

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies Inc (ITCI) is a biopharmaceutical company focused on the development of innovative treatments for central nervous system (CNS) disorders. The company's lead product candidate is lumateperone, a novel antipsychotic agent being evaluated for the treatment of schizophrenia and bipolar depression. Lumateperone's mechanism of action involves modulation of serotonin, dopamine, and glutamate, aiming to improve both positive and negative symptoms of these disorders.
In recent years, Intra-Cellular Therapies has made significant progress in the clinical development of lumateperone. The company successfully completed a Phase 3 clinical trial for schizophrenia, demonstrating favorable efficacy and safety profiles compared to placebo. The results supported the New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), seeking approval for the treatment of schizophrenia in adults. Additionally, lumateperone is being evaluated in a Phase 3 clinical trial for bipolar depression.
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Dr. Sharon Mates Ph.D.
Headquarters
New York
Employees
561
Exchange
NASDAQ
add Intra-Cellular Therapies  to watchlist

Keep an eye on Intra-Cellular Therapies

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Intra-Cellular Therapies 's (ITCI) price per share?

The current price per share for Intra-Cellular Therapies (ITCI) is $77.63. The stock has seen a price change of $0.66 recently, indicating a 0.86% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Intra-Cellular Therapies (ITCI)?

For Intra-Cellular Therapies (ITCI), the 52-week high is $84.89, which is 9.35% from the current price. The 52-week low is $45.5, the current price is 70.62% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Intra-Cellular Therapies (ITCI) a growth stock?

Intra-Cellular Therapies (ITCI) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Intra-Cellular Therapies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Intra-Cellular Therapies (ITCI) stock price performance year to date (YTD)?

As of the latest data, Intra-Cellular Therapies (ITCI) has a year-to-date price change of 10.13%. Over the past month, the stock has experienced a price change of 2.51%. Over the last three months, the change has been 2.75%. Over the past six months, the figure is 18.61%. Looking at a longer horizon, the five-year price change stands at 788.22%.
help

Is Intra-Cellular Therapies (ITCI) a profitable company?

Intra-Cellular Therapies (ITCI) has a net income of -$139.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.7% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -17.18% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $462.18M, with a revenue growth rate of 85.51%, providing insight into the company's sales performance and growth. The gross profit is $428.43M. Operating income is noted at -$159.38M. Furthermore, the EBITDA is -$111.95M.
help

What is the market capitalization of Intra-Cellular Therapies (ITCI)?

Intra-Cellular Therapies (ITCI) has a market capitalization of $7.89B. The average daily trading volume is 504.73K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media